Provided by Tiger Trade Technology Pte. Ltd.

Park Hotels & Resorts Inc.

10.40
+0.02000.19%
Post-market: 10.500.1000+0.96%19:56 EDT
Volume:3.85M
Turnover:39.90M
Market Cap:2.09B
PE:-7.27
High:10.48
Open:10.42
Low:10.15
Close:10.38
52wk High:12.39
52wk Low:8.27
Shares:201.40M
Float Shares:195.63M
Volume Ratio:1.25
T/O Rate:1.97%
Dividend:1.00
Dividend Rate:9.62%
EPS(TTM):-1.4300
EPS(LYR):-1.4300
ROE:-8.31%
ROA:2.12%
PB:0.67
PE(LYR):-7.27

Loading ...

Assessing Park Hotels & Resorts (PK) Valuation After Recent Share Price Underperformance

Simply Wall St.
·
Dec 23, 2025

SAB BIO Announces Positive Confirmatory Clinical Results from the Phase 1 Study of SAB-142 in Development for the Treatment of Stage 3 T1D

GlobeNewswire
·
Dec 17, 2025

GRI Bio Announces Positive Topline Data from its Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)

GlobeNewswire
·
Dec 11, 2025

Park Hotels & Resorts to Sell Three More Non-Core Properties, Reaffirms 2025 Outlook

MT Newswires Live
·
Dec 09, 2025

BRIEF-Park Hotels & Resorts Announces The Sale Of Additional Non-Core Hotels

Reuters
·
Dec 09, 2025

Park Hotels & Resorts Sells Five Non-Core Hotels for $198 Million

Reuters
·
Dec 09, 2025

Park Hotels & Resorts Inc: Reaffirms FY 2025 Outlook With Oct and Prelim Nov Comparable Revpar Results Largely in Line With Expectations

THOMSON REUTERS
·
Dec 09, 2025

Park Hotels & Resorts Announces the Sale of Additional Non-Core Hotels and Provides Update on Non-Core Hotel Disposition Activity and Recent Operating Trends

THOMSON REUTERS
·
Dec 09, 2025

Three Leading Jiangsu City Commercial Banks Compared: Bank of Jiangsu Leads in Profit, Bank of Nanjing in Revenue Growth, Bank of Suzhou in Risk Control

Deep News
·
Dec 05, 2025

Last Patient Completes Biofrontera’s Phase 1 Pharmacokinetics Study of Ameluz® for Treatment of Actinic Keratoses on the Trunk and Extremities

GlobeNewswire
·
Dec 04, 2025

Absci Announces First Participants Dosed in Phase 1/2a HEADLINE™ Trial of AI-Designed Antibody ABS-201™ for Androgenetic Alopecia

GlobeNewswire
·
Dec 04, 2025

Truist Raises Price Target on Park Hotels & Resorts to $12 From $11, Keeps Hold Rating

MT Newswires Live
·
Dec 04, 2025

Press Release: Pasithea Therapeutics Announces Closing of $60 Million Public Offering of Common Stock

Dow Jones
·
Dec 02, 2025

Antengene Announces IND Approval in China for Phase Ib/II Study of ATG-022 (CLDN18.2 ADC) in Combination with KEYTRUDA® (Pembrolizumab) ± Chemotherapy

prnewswire
·
Dec 02, 2025

Park Hotels & Resorts Is Maintained at Equal-Weight by Wells Fargo

Dow Jones
·
Dec 01, 2025

ProMIS Neurosciences to Participate in the 8th Annual Evercore Healthcare Conference

GlobeNewswire
·
Dec 01, 2025

Akebia Announces Establishment of Rare Kidney Disease Pipeline

GlobeNewswire
·
Dec 01, 2025

Pasithea Therapeutics Announces Pricing of $60 Million Public Offering of Common Stock

GlobeNewswire
·
Nov 28, 2025

Alphabet vs NVIDIA Ignites Optical Module Sector: Is This the First Step in Rebuilding A-Share Tech Consensus?

Deep News
·
Nov 27, 2025

Park Hotels & Resorts (PK): Valuation Insights After Discounted San Francisco Hotel Sales and Portfolio Shift

Simply Wall St.
·
Nov 26, 2025